An Overview of Vaccine Development for COVID-19

Simple item page
dc.contributor.authorAlmutary, Abdulmajeed
dc.contributor.authorDua, Kamal
dc.contributor.authorShahcheraghi,Seyed
dc.contributor.authorETAL..
dc.date.accessioned2024-11-11T09:18:47Z
dc.date.available2024-11-11T09:18:47Z
dc.date.issued2021-02-24
dc.descriptionAs demonstrated by COVID-19, new infections caused by RNA viruses which are subject to genetic changes and mutations will continue to create a significant global health danger [Citation1–4]. Despite two past global coronavirus infection epidemics causing SARS and Middle East Respiratory Syndrome, the world remains unprepared to handle the current COVID-19 event effectively, as proven by the fact that COVID-19 has resulted in very many deaths in the world [Citation5,Citation6]. Although COVID-19 is a novel disease, MERS and SARS research has helped investigators understand how the human body reacts to coronaviruses and how the immune system’s response provides defence against the virus [Citation7].
dc.description.abstractThe COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines – peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus – are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date. Keywords: COVID-19, COVID-19 vaccines, SARS-CoV-2
dc.identifier.citationShahcheraghi, S. H., Ayatollahi, J., Aljabali, A. A., Shastri, M. D., Shukla, S. D., Chellappan, D. K., ... & Tambuwala, M. M. (2021). An overview of vaccine development for COVID-19. Therapeutic delivery, 12(3), 235-244.
dc.identifier.doihttps://doi.org/10.4155/tde-2020-0129
dc.identifier.urihttps://repository.adu.ac.ae/handle/1/6969
dc.language.isoen
dc.publisherTaylor & Francis Online
dc.titleAn Overview of Vaccine Development for COVID-19
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
An Overview of Vaccine Development for COVID-19-1.pdf
Size:
1.39 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Biomedical sciences